IPR grants legal rights over innovations, while life materials include genes, microorganisms, and GMOs. Their intersection determines ownership and commercialization of biological resources, shaping biotechnology, healthcare, agriculture, and innovation-driven economic growth.
Present World Scenario of IPRs with Respect to Life Materials
Biotechnology: Increased patents on GMOs and gene-editing technologies, though patent laws differ across countries. Eg- CRISPR-Cas9 patents in the US and restrictions in the EU.
Ethical concerns: Patenting genes and life forms can create monopolies and limit public access to healthcare and seeds. Eg- Myriad Genetics BRCA1 gene patent case.
Developing nations’ approach: often oppose patents on essential medicines and biological resources. Eg- India rejected Novartis Glivec patent under Section 3(d).
TRIPS and global standards:
The TRIPS Agreement requires patent protection but allows safeguards for public health and biodiversity.
With the WTO moratorium ending after MC 14 Meet, countries can now challenge public-health measures like compulsory licensing for harming expected profits.
Open-source movements: Open-access biological initiatives encourage collaborative innovation and protect farmers’ rights. Eg- Open Source Seed Initiative.
Biopiracy: Unauthorized patenting of biological resources and traditional knowledge exploits indigenous communities without fair compensation.
Reasons for Low Commercialization in India
Weak industry-academia linkage: Limited collaboration between research institutions and industries restricts market adoption. Eg- About 13.8% of CSIR patents are licensed.
“Valley of Death” funding gap: Indian universities lack sufficient funding to scale laboratory research and prototypes into commercially viable products through testing and trials.
Weak Patent Quality: Many patents suffer from vague claims, weak disclosures, or insufficient novelty, making them vulnerable to litigation and revocation.
Slow regulatory machinery: Patent approvals and clearances in India often take 5-7 years, delaying commercialization and reducing technological relevance.
Complex tech-transfer policies: Fragmented institutional IP policies create legal uncertainty, discouraging industry partnerships.
Lack of Skilled IP Management: Limited expertise in licensing, prior-art research, and market-oriented commercialization, causing many patents to remain commercially unused.
Misaligned objectives: Universities and researchers prioritize patent filings for rankings and grants, while industries seek scalable, market-ready technologies.
Low absorptive capacity: Most universities lack strong innovation ecosystems and technology-transfer infrastructure beyond elite institutions like IITs.
Poor commercialization infrastructure: India lacks strong incubators and technology-transfer systems.
Global competition: Indian innovations face competition from dominant multinational corporations. Eg- Pfizer global market dominance.
Inadequate Innovation Ecosystem: Support systems such as advanced laboratories, industry mentors, commercialization hubs, and global market integration remain uneven across regions.
Way Forward
Shift from quantity-driven patenting to quality-driven innovation by rewarding commercially viable and genuinely novel research.
Strengthen industry-academia collaboration through technology transfer offices, IP centres, and startup incubation ecosystems. E.g Bayh-Dole model of the United States.
Emulate China’s metrics-based databases, using big data analytics to isolate high-value patents
Develop specialized biotechnology and pharmaceutical IP commercialization hubs on the lines of innovation clusters in South Korea and Israel.
Utilize the 2024 Patent Rules, advance renewal discounts, and expanded startup facilitator schemes to protect emerging technologies.
Align academic incentives away from mere patent counts toward innovation impact, technology transfer, and market adoption.
Enhance venture capital support, FDI confidence, and startup financing by ensuring strong and enforceable intellectual property rights.
Promote uniform state-level IP policies, single-window commercialization portals, and support for SMEs and rural innovators.
With the above measures India can convert its patents into drivers of innovation, technological self-reliance, and the vision of Viksit Bharat 2047.
